<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-5985</journal-id>
<journal-title><![CDATA[Acta Portuguesa de Nutrição]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Port Nutr]]></abbrev-journal-title>
<issn>2183-5985</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Nutrição]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-59852024000400050</article-id>
<article-id pub-id-type="doi">10.21011/apn.2024.3909</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[NOVAS ABORDAGENS NO TRATAMENTO DA OBESIDADE]]></article-title>
<article-title xml:lang="en"><![CDATA[NEW APPROACHES IN THE TREATMENT OF OBESITY]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Ana Patrícia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[Maria João]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pena]]></surname>
<given-names><![CDATA[Angelina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade de Coimbra Faculdade de Farmácia ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<numero>39</numero>
<fpage>50</fpage>
<lpage>54</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-59852024000400050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-59852024000400050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-59852024000400050&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A obesidade é uma doença crónica e prevalente caracterizada pelo excesso de tecido adiposo. Além das repercussões na qualidade de vida, aumenta o risco de agravamento e desenvolvimento de várias outras patologias. Assim, torna-se imprescindível a adoção de um tratamento eficaz com uma abordagem multifatorial. A primeira intervenção no tratamento da obesidade envolve medidas não farmacológicas. Porém, quando não são alcançados resultados satisfatórios é necessária a introdução da terapêutica farmacológica, avaliando o risco-benefício do fármaco em função do doente. O número de fármacos disponíveis atualmente para o tratamento desta patologia é escasso, mas começam a ser aprovadas algumas alternativas eficazes, não deixando de ser crucial a investigação e desenvolvimento de novas moléculas que promovam inovação nesta área terapêutica. O conhecimento da ação destes fármacos pelos profissionais de saúde não médicos, nomeadamente, pelos nutricionistas é fundamental para o sucesso da abordagem multidisciplinar ao doente, pelo que se apresenta uma revisão desses mesmos fármacos, os seus mecanismos e os cuidados a considerar sobre a forma de árvore de decisão.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Obesity is a chronic and prevalent disease that is chacterized by the excess of adipose tissue. Besides its repercussions on the quality of life, it increases the risk of aggravation and development of several other pathologies. Therefore, it is essential to adopt an effective treatment with a multifactorial approach. The first intervention in the treatment of obesity involves non-pharmacological measures. However, when the desired results are not achieved it is necessary to introduce pharmacological therapy, evaluating the risk-benefit of the drug taking into account the patient&#8217;s needs. Furthermore, currently, the number of drugs available for the treatment of this pathology is scarce, making it crucial to research and develop new molecules that promote innovation in this therapeutic area. Knowledge of the action of these pharmaceuticals by non-medical health professionals, namely, nutritionists is crucial for the success of the multidisciplinary approach to the patient, and so it is presented a review of those same pharmaceuticals, their mechanisms and the care to considerate.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Fármacos]]></kwd>
<kwd lng="pt"><![CDATA[Obesidade]]></kwd>
<kwd lng="pt"><![CDATA[Perda de peso]]></kwd>
<kwd lng="pt"><![CDATA[Tratamento farmacológico]]></kwd>
<kwd lng="en"><![CDATA[Drugs]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Loss weight]]></kwd>
<kwd lng="en"><![CDATA[Pharmacological therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="">
<source><![CDATA[Profissionais de Saúde | Dia Mundial da Obesidade]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="book">
<source><![CDATA[PROGRAMA NACIONAL PARA A PROMOÇÃO DA ALIMENTAÇÃO SAUDÁVEL 2022-2030]]></source>
<year>2022</year>
<page-range>1-112 p</page-range><publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Direção Geral de Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[DCW]]></given-names>
</name>
<name>
<surname><![CDATA[Wharton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Canadian Adult Obesity Clinical Practice Guidelines: The Science of Obesity]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="book">
<collab>World Health Organization. Regional Office for Europe</collab>
<source><![CDATA[WHO European Regional Obesity : Report 2022]]></source>
<year>2022</year>
<page-range>1-206 p</page-range><publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yumuk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tsigos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schindler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Busetto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Micic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Guidelines for Obesity Management in Adults]]></article-title>
<source><![CDATA[Obes Facts]]></source>
<year>2015</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>402-24</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camolas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gregório]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[SM de]]></given-names>
</name>
<name>
<surname><![CDATA[Graça]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[OBESIDADE: OTIMIZAÇÃO DA ABORDAGEM TERAPÊUTICA NO SERVIÇO NACIONAL DE SAÚDE]]></source>
<year>2017</year>
<page-range>1-66 p</page-range><publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Direção Geral de Saúde . Programa Nacional para a Promoção da Alimentação Saudável]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="book">
<source><![CDATA[Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentration]]></source>
<year>2010</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<publisher-name><![CDATA[EFSA Journal]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="book">
<collab>World Gastroenterology Organisation</collab>
<source><![CDATA[WGO Practice Guidelines: obesidade]]></source>
<year>2011</year>
<page-range>1-16 p</page-range><publisher-name><![CDATA[World Gastroenterology Organisation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumithran]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Proietto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefit-Risk Assessment of Orlistat in the Treatment of Obesity]]></article-title>
<source><![CDATA[Drug Saf]]></source>
<year>2014</year>
<volume>37</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>597-608</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torgerson]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Hauptman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boldrin]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Sjöström]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>155 161</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="">
<collab>INFARMED I.P</collab>
<source><![CDATA[RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO: XENICAL 120 mg cápsulas]]></source>
<year>1998</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="">
<collab>INFARMED I.P</collab>
<source><![CDATA[RESUMO DAS CARATERÍSTICAS DO MEDICAMENTO: Mysimba 8 mg/90 mg comprimidos de libertação prolongada]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yanovski]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Yanovski]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Naltrexone Extended-Release Plus Bupropion Extended Release for Treatment of Obesity]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1213</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Fujioka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Plodkowski]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Mudaliar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guttadauria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Erickson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<numero>9741</numero>
<issue>9741</issue>
<page-range>595-605</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Apovian]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Still]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wyatt]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity&#8208;related risk factors (COR&#8208;II)]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2013</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>935-43</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Foreyt]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Neil]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2011</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>110-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollander]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Plodkowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4022-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="">
<collab>INFARMED I.P</collab>
<source><![CDATA[RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO: Saxenda 6 mg/ml, solução injetável em caneta pré-cheia]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuffer]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liraglutide: A New Option for the Treatment of Obesity]]></article-title>
<source><![CDATA[Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy]]></source>
<year>2015</year>
<volume>35</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>926-34</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pi-Sunyer]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Astrup]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fujioka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Krempf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2015</year>
<volume>373</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-22</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Tronieri]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Amaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide for the treatment of obesity]]></article-title>
<source><![CDATA[Trends Cardiovasc Med]]></source>
<year>2023</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-66</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamsson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hesse]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>325</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1414</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Færch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jeppesen]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Pakseresht]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Perreault]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10278</numero>
<issue>10278</issue>
<page-range>971-84</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Billings]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Koroleva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>325</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1403</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JPH]]></given-names>
</name>
<name>
<surname><![CDATA[Batterham]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Calanna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gaal]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Once-Weekly Semaglutide in Adults with Overweight or Obesity]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2021</year>
<volume>384</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>989-1002</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="">
<collab>INFARMED I.P</collab>
<source><![CDATA[RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO-Wegovy 2,4 mg FlexTouch solução injetável em caneta pré-cheia]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Khalid]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Neil]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sørrig]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2022</year>
<volume>327</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>138</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="">
<collab>INFARMED I.P</collab>
<source><![CDATA[RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO- IMCIVREE 10 mg/ml solução injetável]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Machineni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2023</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-110</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aizenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Apovian]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[McDonnell]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CagriSema and the link between obesity and type 2 diabetes]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Deenadayalan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Erichsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Knop]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Macura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gurbuz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple-Hormone Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2023</year>
<volume>389</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>514-26</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Igel]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saunders]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Apovian]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Vojta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity]]></article-title>
<source><![CDATA[Curr Atheroscler Rep]]></source>
<year>2016</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>16</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
